Filing Details
- Accession Number:
- 0001209191-18-061113
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-12-06 08:31:35
- Reporting Period:
- 2018-12-03
- Accepted Time:
- 2018-12-06 08:31:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1008848 | Acorda Therapeutics Inc | ACOR | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1360928 | M Lauren Sabella | 420 Saw Mill River Road Ardsley NY 10502 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2018-12-03 | 1,072 | $20.20 | 5,687 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-12-03 | 4,119 | $20.66 | 1,568 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.0600 to $20.2500 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Sales pursuant to a 10b5-1 plan.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.2500 to $20.7900 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Billionaire Hedge Funds
